Business Description
Alimera Sciences Inc
NAICS : 325412
SIC : 2834
Description
Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | -0.42 | |||||
| Debt-to-Equity | -2.44 | |||||
| Debt-to-EBITDA | -4.35 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -13.02 | |||||
| Beneish M-Score | -2.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.4 | |||||
| 3-Year FCF Growth Rate | 33.5 | |||||
| 3-Year Book Growth Rate | 18.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.81 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.36 | |||||
| 9-Day RSI | 23.04 | |||||
| 14-Day RSI | 26.5 | |||||
| 6-1 Month Momentum % | -57.45 | |||||
| 12-1 Month Momentum % | -61.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.88 | |||||
| Quick Ratio | 0.82 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 101.54 | |||||
| Days Sales Outstanding | 126.36 | |||||
| Days Payable | 364.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.1 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.54 | |||||
| Operating Margin % | -22.72 | |||||
| Net Margin % | -34.1 | |||||
| ROA % | -35.51 | |||||
| ROIC % | -39.83 | |||||
| ROC (Joel Greenblatt) % | -74.67 | |||||
| ROCE % | -40.32 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.17 | |||||
| EV-to-EBIT | -5.25 | |||||
| EV-to-EBITDA | -6.64 | |||||
| EV-to-Revenue | 1.25 | |||||
| EV-to-Forward-Revenue | 1.02 | |||||
| EV-to-FCF | -4.58 | |||||
| Earnings Yield (Greenblatt) % | -19.05 |
How Alimera Sciences Inc (ALIM) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALIM
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 54.059 | ||
| EPS (TTM) ($) | -2.64 | ||
| Beta | 1.36 | ||
| Volatility % | 58.15 | ||
| 14-Day RSI | 26.5 | ||
| 14-Day ATR ($) | 0.198763 | ||
| 20-Day SMA ($) | 1.82852 | ||
| 12-1 Month Momentum % | -61.25 | ||
| 52-Week Range ($) | 1.3 - 7.92 | ||
| Shares Outstanding (Mil) | 7.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alimera Sciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alimera Sciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alimera Sciences Inc Frequently Asked Questions
What is Alimera Sciences Inc(ALIM)'s stock price today?
The current price of ALIM is $1.35. The 52 week high of ALIM is $7.92 and 52 week low is $1.30.
When is next earnings date of Alimera Sciences Inc(ALIM)?
The next earnings date of Alimera Sciences Inc(ALIM) is 2023-05-09 Est..
Does Alimera Sciences Inc(ALIM) pay dividends? If so, how much?
Alimera Sciences Inc(ALIM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
